As filed with the Securities and Exchange Commission on March 23, 2023
Registration No. 333-248996
Registration No. 333-263999
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-248996
Post-Effective Amendment No. 1 to Form
S-8 Registration Statement No. 333-263999
UNDER
THE
SECURITIES ACT OF 1933
Metacrine, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
Delaware |
|
47-2297384 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
4225 Executive Square, Suite 600
San Diego, California |
|
92037 |
(Address of principal executive offices) |
|
(Zip Code) |
Amended and Restated 2015 Equity Incentive Plan
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
(Full titles of the plans)
Michael York
President
and Chief Executive Officer
Metacrine, Inc.
4225 Executive Square, Suite 600
San Diego, California 92037
(858) 369-7800
(Name, address, including zip code, and telephone number, including area code, of agent for service)
With copies to:
Karen E. Deschaine, Esq.
Carlos Ramirez, Esq.
Cooley LLP
10265 Science
Center Drive
San Diego, California 92121
(858) 550-6000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒